Physician profile
Gary Anthony Smith
NPI 1528271848
$14,113.00
in general payments reported to CMS, 2019-2025
42 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,610 · 2021: $2,434 · 2022: $1,997 · 2023: $2,244 · 2024: $2,238 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,224.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,703.44 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,967.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,101.66 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,048.49 | 2019-2025 | |
| Lilly USA, LLC | $932.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $884.91 | 2020-2025 | Nexletol |
| Amgen INC. | $396.04 | 2019-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $389.04 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.86 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $359.07 | 2020-2024 | Eliquis, Camzyos |
| Abbvie INC. | $352.63 | 2021-2025 | Vraylar |
| Sanofi-Aventis U.S. LLC | $272.05 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $260.69 | 2019-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.57 | 2024-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $233.02 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $220.37 | 2022-2024 | Vyepti |
| Amarin Pharma, INC. | $178.97 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $150.18 | 2021-2025 | Uzedy |
| Cequr Corporation | $111.79 | 2022-2024 | Cequr Simplicity |
| Dexcom, INC. | $92.74 | 2021-2025 | Dexcom G6 Transmitter |
| Myriad Women'S Health, INC. | $92.46 | 2023 | Myrisk |
| Gilead Sciences, INC. | $85.03 | 2024-2025 | Vemlidy |
| Ironwood Pharmaceuticals, INC | $83.91 | 2021-2022 | |
| Aytu Biopharma, INC. | $61.82 | 2021-2022 | |
| Mannkind Corporation | $55.29 | 2019-2021 | |
| Neotract INC. | $52.65 | 2019 | |
| Insulet Corporation | $42.87 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $38.42 | 2021 | |
| Corcept Therapeutics | $37.93 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $37.90 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phadia US INC. | $34.35 | 2024-2025 | Immunocap |
| Corium, LLC | $28.46 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $24.56 | 2024 | |
| Abbott Laboratories | $23.51 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $21.91 | 2024 | Opsumit, Uptravi |
| Lifescan, INC. | $20.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2019 | |
| Eisai INC. | $17.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2023 | Seglentis |
| Phathom Pharmaceuticals, INC. | $16.00 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $14.75 | 2021 | |
| Mylan Specialty L.P. | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.